Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.

ABSTRACT:

Background

Isocitrate dehydrogenase (IDH) mutated diffuse lower-grade gliomas (dLGG) are infiltrating brain tumors and increasing evidence is in favor of early multimodal treatment. In a Scandinavian population-based setting, we wanted to study treatment patterns over the last 15 years, focusing on the short-term postoperative course to better understand the potential negative consequences of treatment.

Methods

Patients ≥ 18 years with primary IDH-mutated dLGG grade 2 and 3, operated between January 2007-June 2021 were identified. Patients were divided into subgroups (2007-2011, 2012-2016, and 2017-2021) and comparisons regarding tumor- and disease characteristics, treatment, and postoperative outcome were performed.

Results

We identified 202 patients (n = 61, 2007-20

SUBMITTER: Svenjeby C 

PROVIDER: S-EPMC9758083 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature